3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
Tumor-Agnostic
6
Sarcoma
4
Genitourinary
2
Breast
2
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Classical hematology
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Somatostatinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Doxorubicin
4
Sunitinib
3
Radiosurgery
3
Everolimus
3
pembrolizumab
2
exemestane
2
Tamoxifen
2
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Filgrastim
2
Biopsy
2
Bevacizumab
2
3-Iodobenzylguanidine
2
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
penpulimab
1
pasireotide
1
mercaptoundecahydrododecaborate
1
lutetium Lu 177 dotatate
1
lanreotide
1
ganitumab
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
entrectinib
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
regorafenib
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled